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Abbreviations:  23 
HPP: paediatric-onset hypophosphatasia 24 
TNSALP: nonspecific alkaline phosphatase  25 
ALP, ALKP1: Alkaline phosphatase 26 
NBT/BCIP: nitroblue tetrazolium salt and 5-bromo-4-chloro-3-indolyl-phosphate  27 
NADPH: Nicotinamide adenine dinucleotide phosphate 28 
pNPP: para-Nitrophenylphosphate  29 
EMIA: Enzyme Mediated Immunometric Assay 30 
EIA: Enzyme Immunoassay 31 
TnI: cardiac troponin I 32 
hCG: β-human chorionic gonadotropin 33 
CHO: Chinese Hamster Ovary 34 
IL6: Interleukin 6 35 
fT4: free T4 (thyroxin)  36 
TSH: thyroid stimulating hormone   37 
LH: Luteinising hormone  38 
FSH: Follicle stimulating hormone  39 
BAP: bone alkaline phosphatase 40 
HCL: hydrochloric acid 41 
HRP: horseradish peroxidase 42 
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Abstract 43 
Background: Asfotase alfa (STRENSIQ®, Alexion Pharmaceuticals, Inc.) is the only approved 44 
treatment for patients with paediatric-onset hypophosphatasia, a disease caused by a mutation 45 
in the tissue-nonspecific alkaline phosphatase (TNSALP) gene. ALP is often used as signalling 46 
system in routine immunoassays. Because asfotase alfa contains the active site of the full ALP 47 
enzyme, it can catalyse the substrate as the antibody-conjugated ALP would within an assay. 48 
Therefore, its presence in a treated patient’s sample may generate false positive or false 49 
negative results. We investigated whether the presence of asfotase alfa within a sample induced 50 
interference in immunoassays that utilise ALP or alternative detection systems.  51 
Methods: Asfotase alfa was added to samples at concentrations from 0.08-5 µg/mL. Asfotase 52 
alfa was detected in all ALP assays but ALKP1 (RayBiotech). We observed no changes in 53 
normetanephrine and noradrenaline (IBL) at any asfotase alfa concentration. However, asfotase 54 
alfa significantly interfered in an oxytocin (ENZO) assay in non-extracted samples. Extraction 55 
using a C18 column eliminated the interference. 56 
Results: No interference was observed on automated analysers using alternative detection 57 
system (COBAS fT4 and TSH; Advia Centaur FSH, fT4; Architect LH; FSH). Immulite 2000 58 
fT4, TSH, testosterone and hCG (ALP based) showed no interference. However the presence 59 
of asfotase alfa resulted in a dose-dependent increase of Troponin I signal. 60 
Conclusion: The presence of asfotase alfa must be taken into consideration when analysing 61 
blood samples in treated patients to avoid any risk of misinterpretation of false 62 
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Statement 67 
Asfotase alfa is used in the treatment of hypophosphatasia. It contains the active site of alkaline 68 
phosphatase (ALP). Here we show that it interferes in immunoassays that utilize ALP-69 
conjugated antibodies (Troponin I, Oxytocin). This can result in false positive or false negative 70 
measurements. Asfotase alfa treatment should therefore be disclosed when requesting 71 
biochemical analyses of patient samples and should be considered in the interpretation of 72 
results.   73 
1. Introduction 74 
Asfotase alfa (Strensiq®, Alexion Pharmaceuticals, Inc.) is the only approved treatment for 75 
patients with paediatric-onset hypophosphatasia (HPP) (1).  HPP is an inherited metabolic 76 
disorder, the result of a loss-of-function mutation, which results in low activity of the tissue-77 
nonspecific alkaline phosphatase (TNSALP), an enzyme that plays a role in bone 78 
mineralization. The defect in TNSALP induces altered mineralisation of bones that become 79 
prone to fracture and deformity and this can result in functional impairments and pain (2,3). In 80 
2011, the prevalence of severe forms of HPP in Europe was estimated at 1 per 300,000 live 81 
births (4). However the exact prevalence for the different forms is not clear (5). Asfotase alfa 82 
is injected subcutaneously to patients three or six times per week. With a bioavailability of 46-83 
98%, and a half-life of 2.3±0.6 days, asfotase alfa reaches highest blood concentrations 84 
between 24 to 48 hours post injection (6).  85 
Alkaline phosphatase (ALP) is used as the measuring/signalling system in many routine assays 86 
for proteins, hormones and other small molecules. ALP is usually linked to an antibody directed 87 
against the molecule of interest (analyte) in the immunoassay. After addition of a substrate 88 
molecule (nitroblue tetrazolium salt and 5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP), 89 
Nicotinamide adenine dinucleotide phosphate (NADPH), or para-Nitrophenylphosphate 90 
(pNPP)), the ALP converts the substrate to generate a colour change that can be estimated using 91 
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a spectrophotometer. In a classical “sandwich” assay, Enzyme Mediated Immunometric Assay 92 
(EMIA), or non-competitive assay, the colour produced is proportional to the concentration of 93 
analyte captured between the capture and the detection antibodies. An alternative type of assay 94 
is an Enzyme Immunoassay (EIA), or competitive assay, in which the analyte of interest in the 95 
sample competes with an ALP-labelled analyte. In this type of assay the colour produced is 96 
inversely proportional to the concentration of the analyte.  These assay formats are commonly 97 
employed in large multichannel analysers.  98 
Asfotase alfa is a recombinant glycoprotein containing the catalytic domain of TNSALP. 99 
Because of the presence of this active site, asfotase alfa is able to catalyse the substrate in a 100 
similar manner to antibody-conjugated ALP. Depending on the type of assay format 101 
(competitive or non-competitive) and the concentration of asfotase alfa present in a patient’s 102 
sample it is possible to generate a false positive or a false negative result. In competitive assays, 103 
the higher the concentration of asfotase alfa, the lower the concentration of the analyte that will 104 
be reported, as this will give the impression that little “cold” (unlabelled) analyte is in the 105 
specimen. In a non-competitive assay, the amount of signal generated is proportional to the 106 
concentration of the analyte in the sample, so the higher the concentration of asfotase alfa the 107 
greater the signal produced, and so a higher concentration of the analyte will be reported. A 108 
limited number of case studies have shown that asfotase alfa may cause interference with some 109 
assays such as testosterone (7), cardiac troponin I (TnI) and β-human chorionic gonadotropin 110 
(hCG) (8). In this study we tested a range of assays that used ALP as detection system and 111 
assay using a different detection system. We also tested a range of analysers commonly used 112 
in clinical laboratories. 113 
The consequence of false negative and false positive results may be significant for patients who 114 
could experience misdiagnosis of additional conditions. We investigated whether the presence 115 
of asfotase alfa within a sample induced interference in immunoassays, i.e. sandwich and 116 
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competitive assays using base-plate and automated analyser technology with various detection 117 
systems.  118 
 119 
2. Material and methods 120 
2.1 Samples 121 
Anonymized urine and blood samples were provided by Department of Laboratory Medicine 122 
at the Norwich and Norfolk University Hospital in accordance with local ethical committee 123 
approval (9).   124 
Samples were pooled according to their matrix. Asfotase alfa was added to the sample pool at 125 
final concentrations of 5.0, 2.5, 1.25, 0.63, 0.31, 0.16 and 0.08µg/mL. An aliquot of the original 126 
pool without addition of asfotase alfa was also measured as control (asfotase alfa 0µg/mL). 127 
Measurements were reproduced a minimum of 3 times (new preparation) for each assay. 128 
2.2 Reagents 129 
Asfotase alfa was kindly provided by Alexion Pharmaceuticals Inc. as a solution of 100 130 
mg/mL. Asfotase alfa was produced by recombinant DNA technology using mammalian 131 
Chinese Hamster Ovary (CHO) cell culture. The solution excipients are sodium chloride, 132 
sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate in 133 
water. 134 
For manual assays, oxytocin (ENZO Life Science Inc., Lausen, Switzerland), Normetanephrine 135 
(IBL International GmbH, Hamburg, Germany), and Alkaline Phosphatase (ALKP1, 136 
RayBiotech, Inc., Norcross, USA) ELISA kits were purchased from Oxford Biosystems 137 
(Milton Park, UK). Interleukin 6 (IL6) was purchased from R&D Systems (Abingdon, UK). 138 
COBAS 6000 assays for ALP, free T4 (fT4) and thyroid stimulating hormone (TSH) were 139 
purchased from Roche Diagnostics (Burgess Hill, UK). Assays for the Architect c16000 140 
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analyser, ALP, Luteinising hormone (LH) and Follicle stimulating hormone (FSH) were 141 
purchased from Abbott (Maidenhead, UK). Assays for Centaur XPT (Siemens, Camberley, 142 
UK) were fT4, TSH (TSH3-UL) and ALP (ALP_2c). Assays for Immulite 2000 (Siemens) 143 
were testosterone, TnI, hCG, fT4 and TSH. Liaison XL bone alkaline phosphatase (BAP) assay 144 
was purchased from DiaSorin (Dartford, UK). Table 1 details assay characteristics and 145 
detection systems. 146 
All assays were used following manufacturer’s instructions. All assays were performed on the 147 
same day as the sample preparation.  148 
Statistical Analysis: 149 
Statistical analysis was performed using SPSS software 25 (IBM Corporation, Armonk, New 150 
York, USA). Normality of data was confirmed by Shapiro-Wilk test. Data were analyzed by 151 
one way ANOVA to find potential significant effect of asfotase alfa concentration on 152 
specimen parameters. Data of different asfotase alfa concentrations were compared with the 153 
control group (no asfotase alfa) using Dunnett (equal variance) and Dunnett T3 (non-equal 154 
variance).  155 
 156 
3. Results 157 
The presence of asfotase alfa was detected in the ALP chemistry assays (COBAS, Centaur and 158 
Architect ALP) that measured the activity of the enzyme. ALP showed a significant (ANOVA, 159 
p<0.0001) linear increase in concentration with increasing asfotase alfa concentration (Fig 1A) 160 
for all three assays. Architect ALP was only measured to 1.25µg/mL and a linear projection 161 
was estimated. We also observed a stronger increase (p<0.05) for the Centaur XPT assay as 162 
compared to the other two (COBAS, Architect). We observed a strong cross-reactivity of 163 
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asfotase alfa with the Liaison XL BAP assay (p<0.001; Fig 1B). The signal increased very 164 
quickly and a hook effect was observed for concentrations of asfotase alfa > 0.31 µg/mL. 165 
The COBAS 6000, Advia Centaur XPT and Architect analyser’s immunoassays use acridium 166 
ester and ruthenium technology to measure the analyte concentrations. These assays, COBAS 167 
fT4 and TSH, Centaur FSH and fT4 and Architect FSH and LH, were not affected by the 168 
presence of asfotase alfa, at any concentration (Fig 2A, 2B and 2C, respectively). The 169 
concentration of the analytes of interest did not change by more than 2.4%, 9.7% and 7.9% 170 
from the original sample without asfotase alfa for assays run on the COBAS 6000, the Advia 171 
Centaur XPT and the Architect respectively. We observed no significant change in the 172 
concentration of TSH, fT4, testosterone and hCG when using the ALP-detection based assay 173 
on the Siemens Immulite 2000 instrument, at any asfotase alfa concentration (Fig 2D and 2E).  174 
However, asfotase alfa induced a dose-dependent increase of signal/concentration in TnI (Fig 175 
2 F, p<0.05). This effect was greatest when using serum as compared to lithium-heparin 176 
plasma. 177 
All the manual assays were selected because they used an ALP detection system (or measure 178 
ALP activity, Raybiotech). We observed no effect of asfotase alfa on the concentration of the 179 
analytes (normetanephrine, extracted oxytocin) measured (Fig 2G and 2H respectively). We 180 
observed low concentrations of normetanephrine in the urine pool, we therefore spiked the 181 
sample with 250µg/L of normetanephrine (Calibrator). The measurement of total 182 
normetanephrine required hydrolyzation with HCL 0.1M and acetylation using 183 
dimethylformamide. This step is followed by a dilution of the acetylated samples 1:100 with 184 
assay buffer. We did not observe any significant effect of asfotase alfa when measuring total 185 
normetanephrine in urine samples (Fig 2G). We also tested for free normetanephrine, which 186 
does not require the hydrolyzation, but only acetylation and therefore dilution, and found no 187 
interference of the asfotase alfa (not shown). Although the imprecision in the assay was 188 
relatively high (up to 20%), we observed no effect on IL6 (Fig 2G).  We observed a very low 189 
Page 9 of 18 
 
concentration of oxytocin in our sample pools and therefore proceeded with spiked (using 190 
calibrator at 50, 100 and 150pg/mL) samples. We observed that asfotase alfa significantly 191 
interfered in the oxytocin assay (Fig 2H, p<0.001), in a concentration-dependant manner when 192 
samples were not extracted. Extraction with a C18 cartridge is recommended by the supplier 193 
when using samples with high matrix content such as plasma samples. We therefore extracted 194 
the plasma pool containing 250pg/mL of oxytocin. We observed no interference of asfotase 195 
alfa at any concentration. We observed no significant change in the absorbance (Fig 1B) and 196 
therefore the concentration of ALP measured using the RayBiotech assay for ALKP1 at any 197 
asfotase alfa concentration. We observed a relatively high imprecision in the assay but no 198 
consistent changes in OD or concentration and an effect of asfotase alfa was excluded. The 199 
maximum absorbance variation within one experiment was 15%. 200 
 201 
4. Discussion 202 
Asfotase alfa (STRENSIQ®, Alexion Pharmaceuticals, Inc.) is the first approved ALP 203 
replacement therapy for treatment of HPP (1). This glycoprotein contains the catalytic domain 204 
of human tissue non-specific ALP (TNSALP) (10) as well as the Fc region of human 205 
immunoglobulin G1, and a sequence of ten L-aspartate residues that allows the asfotase alfa to 206 
target the bone.  207 
Due to the presence of the active site of TNSALP in asfotase alfa, assays that measure the 208 
activity of endogenous ALP, such as those employed on the Roche COBAS 6000, Siemens 209 
Advia Centaur XP and Abbott Architect c16000 analysers, can react with the asfotase alfa in 210 
the blood sample. We found that high concentrations of asfotase alfa in samples required 211 
dilution of the samples and we demonstrated that these assays have sufficient linearity to 212 
“measure” at least 5µg/mL of asfotase alfa in the sample. In treatment of paediatric-onset HPP, 213 
the recommended dosage of asfotase alfa is 6mg/kg per week given as 1 or 2 mg on a single 214 
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day. A pharmacokinetics study on 38 HPP patients treated with asfotase alfa showed maximum 215 
ALP blood concentrations Cmax of 1794 ± 690 ng/mL for patients under the age of 5 and 2108 216 
± 788 ng/mL for patients above the age of 5 (10). We tested concentrations covering the range 217 
of observed ALP Cmax observed in both adult and pediatric patients treated with asfotase alfa. 218 
It is interesting to note that all COBAS ALP and Architect ALP showed similar increased in 219 
measured ALP, however the Centaur XPT ALP was significantly higher at 5µg/mL (p<0.05). 220 
These results highlight the need of standardized assay for ALP in order to monitor asfotase alfa 221 
in an harmonised manner across the laboratories. In the manual immunoassay for ALP from 222 
Raybiotech the presence of asfotase alfa did not affect the ALP result obtained. We suggest 223 
that at least one of the antibodies against ALP (ALKP-1) in this assay is not directed against 224 
the active site of the protein and as a result, this assay was specific for the measurement of 225 
endogenous ALP. ALP in this assay is detected using an HRP-labelled antibody. The assay is 226 
therefore based on the quantity of protein (mass assay) rather than the activity. In order to test 227 
the hypothesis that a mass assay employing antibodies not directed against the active site of 228 
ALP would be preferential for measuring endogenous ALP in patients receiving asfotase alfa 229 
we measured bone-specific ALP using the Liaison XL assay (mass assay) from DiaSorin. All 230 
samples with added Asfotase alfa were above the linear range of the assay (120 ng/L) and we 231 
observed a sharp increase in signal and hook-effect at concentration of asfotase alfa of about 232 
0.3µg/mL.  233 
Immunoassays we tested that employed analyte-specific antibodies labelled with acridium ester 234 
or rutenium detection systems (fT4, FSH, LH, and TSH) showed no effect of asfotase alfa on 235 
the concentrations measured. The oxytocin and normetanephrine assays are immunoassays that 236 
are based on the use of detection antibodies that are linked to an ALP detection system. In the 237 
final step of the assay, the substrate for ALP, pNPP or NAPDH, respectively, is added and the 238 
colour develops depending on the concentration of the specific analyte present.  239 
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The measurements of oxytocin (ENZO) in urine samples showed an interference effect of 240 
asfotase alfa within the assay when the samples were not extracted. It is a competitive 241 
immunoassay, where the more oxytocin present in the sample the lower the absorbance 242 
measured. As the concentration of asfotase alfa increased, the absorbance increased 243 
significantly, resulting in a false negative reading of the concentration of oxytocin. The 244 
estimated ODs for oxytocin were quickly above the lower limit of detection for the lowest 245 
calibrator, asfotase alfa brought the absorbance to saturation, and all the samples containing 246 
asfotase alfa resulted in undetectable oxytocin concentrations.  247 
The normetanephrine assay is also a competitive immunoassay. This test necessitates the 248 
acylation of the samples with prior hydrolysation (for total normetanephrine) or no 249 
hydrolysation (for free normetanephrine). We tested both conditions, and spiked 250 
normetanephrine in some samples to ensure the presence of the analyte. We did not detect any 251 
interference of asfotase alfa in this assay. The volume of sample used was very small (10µL) 252 
and highly diluted (1:100) before being analysed. The conditions of use for detection of 253 
normetanephrine may be sufficient to decrease the asfotase alfa concentration resulting in no 254 
effect in the assay.  255 
A case of false positivity due to AA for cardiac TnI and β-hCG has been described previously 256 
(8). Analytes were measured on a Beckman Coulter DxI 800 and both assays used ALP as the 257 
detection system. Most recently, Sofronescu et al. (7) described the case of a patient whose 258 
blood testosterone showed falsely decreased results post treatment with asfotase alfa. The 259 
patient suffered from HPP and was treated with testosterone for his secondary hypogonadism. 260 
After starting treatment with asfotase alfa, his testosterone concentrations were undetectable 261 
while his free testosterone was normal. Testosterone was measured on a Coulter 800 DXI using 262 
ALP as detection system. The author also suggested the interference could be due to the 62% 263 
sequence homology between the Fc region of the immunoglobulin G1 present in asfotase alfa 264 
and the Fc fragment of the mouse anti-testosterone antibody used in the assay. We did not have 265 
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access to a DxI to reproduce these results. We therefore tested the interference of these analytes 266 
on the Siemens Immulite 2000, using ALP as the detection system. We did not observe any 267 
effect of asfotase alfa for testosterone or hCG suggesting an alternative way of measuring these 268 
analytes for patients treated with asfotase alfa. However, we did observe an interference when 269 
measuring TnI. Interference of ALP in assays for cardiac TnI has been observed by several 270 
groups on various analytical platforms using ALP/pNPP as detection system (8,12–15), 271 
whether from elevated ALP in patients with suspected myocardial infarction, or from carry-272 
over from an elevated sample. Asfotase alfa is used in patients with HPP to reduce the 273 
accumulation of extracellular TNSALP substrates such as inorganic pyrophosphate (PPi), 274 
pyridoxal-5’-phosphate (PLP) and phosphoethanolamine (PEA). It has been suggested that 275 
asfotase alfa may hydrolyse TNSALP substrates to a higher extend than anticipated due to its 276 
continuous activity post blood collection (11). Although not tested in this study, this effect 277 
must not be ignored. It may be of consideration to implement the use of tubes containing 278 
phosphatase inhibitors (such as levamisole or Bromotetramisole oxalate) when collecting blood 279 
samples from a patient treated with asfotase alfa. 280 
 281 
5. Conclusion 282 
Most assays tested using ALP detection systems were sufficiently specific not to show 283 
interference with asfotase alfa up to a serum concentration of 5µg/mL (upper Cmax 2108 ± 284 
788 ng/mL for patients with HPP). Oxytocin required extraction of samples in that assay type 285 
to demonstrate this specificity. The effects observed depended on the method of ALP detection 286 
used. When high sensitivity is required, some manufacturers still rely on the use of ALP 287 
detection systems, although use of ALP as a detection system has been decreasing over recent 288 
years and being replaced with horseradish peroxidase (HRP) or acridium ester in many 289 
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automated assays. Alternative assays can be found that lack interference, i.e. Siemens 290 
testosterone or hCG instead of Beckman Coulter DxI.  291 
When measuring TnI, the likelihood of misdiagnosing myocardial infarction in patients treated 292 
with asfotase alfa remains low, but cannot be excluded, and consultants should ensure 293 
laboratories are aware of the presence of asfotase alfa in samples sent for analysis. The presence 294 
of asfotase alfa must be taken into consideration when analysing blood samples using ALP-295 
based technology to avoid any risk of misinterpretation of false positive/negative results. 296 
Various methodologies such as addition of a blocking reagent, or dilution of the sample in non-297 
immune serum, can be used to confirm interference (16,17). It is vital for the clinicians and 298 
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Analyte Analyser/Assay Provider Detection System Sample type Unit 
Analyte concentration in 
original pool  
(mean  ± SEM) 
Max change              




          
ALP 
COBAS6000 Roche Diagnostics 
ALP/pNPP Serum 
U/L 81.7 ± 3.0 17831 ± 1107 POS <0.001 
Architect c16000 Abbott U/L 199 ± 0.0 14700 ± 6789 POS <0.001 








ALKP Manual RayBiotech Inc. HRP Serum pg/mL 54.0 ± 11.0 17.7 ± 10.6 no 0.249 
          
TSH 
COBAS6000 Roche Diagnostics Ruthenium Serum mIU/L 3.7 ± 0.1 1.0 ± 1.0 no 0.990 
ADVIA Centaur XPT Siemens acridinium ester Serum mIU/L 1.9 ± 0.0 7.4 ± 3.2 no 1.000 
Immulite 2000 Siemens ALP/pNPP Serum mIU/L 1.9 ± 0.1 11.6 ± 1.0 no 0.756 
          
free T4 
COBAS6000 Roche Diagnostics Ruthenium Serum pmol/L 15.4 ± 0.1 1.5 ± 0.7 no 0.384 
ADVIA Centaur XPT Siemens Ruthenium Serum pmol/L 17.9 ± 0.4 6.7 ± 0.8 no 0.890 
Immulite 2000 Siemens ALP/pNPP Serum pmol/L 17.1 ± 0.4 8.4 ± 3.3 no 0.089 
          
Testosterone Immulite 2000 Siemens ALP/pNPP 
Serum 
ng/dL 
136.3 ± 1.2 
25.2 ± 13.9 no 0.395 
33.5 ± 3 
Li-Hep 175.4 ± 8.2 20.9 ± 4.1 no 0.937 
hHCG Immulite 2000 Siemens ALP/pNPP 
Serum 
ng/mL 
<2.0 ± 0.0  
14.2 ± 5.3 
no 
0.487 
46.2 ± 2.0 
Li-Hep <2.0 ± 0.0 13.5 ± 4.7 0.460 
Troponin I Immulite 2000 Siemens ALP/pNPP 
Serum 
ng/mL 








          
LH Architect c16000 Abbott acridinium ester EDTA IU/L 10.5 ± 0.3 6.0 ± 1.8 no 0.933 
FSH Architect c16000 Abbott acridinium ester EDTA IU/L 26.5 ± 3.5 4.8 ± 2.3 no 0.945 
          
IL6 Manual R&D Systems ALP/pNPP Serum pg/mL 6.2 ± 1.4 19.9 ± 10.0 no 0.210 
Normetanephrineb Manual IBL International GmbH ALP/pNPP Urine µg/L 581.4 ± 169.4 14.7 ± 8.9 no 0.413 
Oxytocinc non-
extracted Manual ENZO life Science Inc. ALP/pNPP 
Urine 
pg/mL 
130.5 ± 69.6 360.3 ± 88.3 NEG 0.001 
Oxytocin extracted EDTA† 70.7 ± 5.4 14.8 ± 5.8 no 0.121 
 363 
Table 1: Table showing the various assays tested for interference with asfotase alfa and their characteristics. The table also include the original analyte 364 
concentration in the pool tested (before addition of asfotase alfa) and the p value from the one-way ANOVA test. a measured at 1.25 µg/mL of asfotase 365 
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alfa, samples having not been diluted for values above the assay range; b Normetanephrine added at 250, 324 and 612 µg/L; original urine pool <18µg/L; 366 
c non spiked [Oxytocin] <15pg/mL- spiked with 50, 100, 150pg/mL. LH = Li-Heparin plasma; † containing Aprotinin, tested extracted and non-367 
extracted; PNPP = p-nitrophenyl phosphate; HRP = horseradish peroxidase 368 
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Figure 1: Graph showing the effect of asfotase alfa ALP neasurement using various platforms. 369 
Asfotase alfa can be detected on automated platforms for measurement of ALP. (A) Assays on 370 
Centaur XPT (Siemens) and Architect (Abbott) and COBAS 6000 (Roche) showed linear 371 
increase of ALP concentration with increased asfotase alfa concentrations up to 5µg/mL. A 372 
hook effect was observed in the Liaison XL (DiaSorin) assay for Bone ALP (BAP). (B) Manual 373 
assay ALPK1 (Raybiotech) showed no interference of asfotase alfa. 374 
 375 
Figure 2: Graph showing the effect of asfotase alfa on various immunoassay. 376 
Automated assays (A) COBAS 6000 fT4 and TSH (B) Advia Centaur fT4 and TSH and  (C) 377 
Architect LH asnd FSH and Immulite 2000 (D) fT4 and TSH (E) testosterone and hCG showed 378 
no interference from the presence of asfotase alfa. Immulite 2000 troponin I (F) showed a dose-379 
dependent interference in both serum and lithium-heparin plasma samples. In manual assays 380 
(G) IL6 and normetanephrine and (H) oxytocin showed no interference. When samples were 381 
not extracted, asfotase alfa causes interference (false negative) in the oxytocin measurement. 382 
